The clinical trial’s objective is to establish the safety profile of extended application of active cellular immunotherapy (ACI) prepared from repeated leukapheresis. The safety of the second cycle of active cellular immunotherapy involving second leukapheresis will be assessed in patients, who successfully received all doses of active cellular immunotherapy (ACI) in Study SP003, and who were without objective progression of the disease during Study SP003.